News Release
INDIANAPOLIS — Eli Lilly and Co. is expanding its mental health portfolio with the acquisition of AtaiBeckley, a psychedelic drug developer, in a deal valued at up to $3.8 billion.
“Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works,” said Carole Ho, executive vice president and president, Lilly Neuroscience. “Advancing AtaiBeckley’s investigational therapies gives us a real chance to change that.”…